AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04695002 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control
Description: Citizens in the control group participate in the standard course of vocational rehabilitation, without the use of MIRA app. Citizens are referred from the jobcenter if the case manager assesses that a health condition limits the citizen's ability to resume work. The typical course of rehabilitation lasts 4-12 weeks, and is managed by a physiotherapist, a psychologist and a physician. Depending on the condition of the citizen, the rehabilitation may be managed by only two of the three professionals. During the course of rehabilitation, the citizen may consult the team with varying frequency. If physical rehabilitation is part of the prescribed rehabilitation, the citizen shows up twice per week for several weeks of supervised exercise, whereas rehabilitation courses where self-management is in focus, only biweekly consultations may be provided. The decisions and planning of contents and duration of the rehabilitation programme is done in collaboration with the citizen.
Study NCT05203978 — intervention group
Intervention type: PROCEDURE
Intervention: colonoscopy
Description: Colonoscopy
Study NCT05694910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki has based on the belief that disease occurs when an energy center is blocked, and that the energy is transmitted through touch. In distance Reiki, Reiki practitioners followed the traditional Usui Reiki protocol healing.
Study NCT05203367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAR502
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg).
Study NCT05203367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment
Study NCT04842474 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gaze stability exercises and balance exercises
Description: Gaze stability exercises will be performed while patients are in a seated position. Each exercise will last for 30 seconds and be done in phases that included; eyeball movement, saccadic eye movement, pursuit eye movement, vergence eye movement, and vestibular-ocular reflex exercise. Balance exercises will be performed in a standing position including both static and dynamic training with or without closing eyes.
Study NCT01004016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPS-0373
Study NCT01004016 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04922983 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Used as placebo
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Arterial blood gases
Description: Measurement of arterial oxygen and tension and arterial dioxide tension, calculation of arterial partial oxygen tension to inspiratory oxygen fraction (PaO2/FiO2) ratio
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Respiratory rate (RR)
Description: Measurement of respiratory rate by waveform analysis using a ventilator
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulseoximeter
Description: Peripheral capillary oxygen saturation (SpO2) measurement and the ROX-index calculation (SpO2/FiO2/RR)
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of accessory respiratory muscles work
Description: Patrick score calculation. Score: 0. No visible tonic or phasic use of neck muscles. 1. Neck muscles taut but with no respiratory modulation (i.e., tonic activity). 2. Mild respiratory modulation in neck muscle contraction. 3. Moderate phasic activity (no supraclavicular or intercostal indrawing). 4. Vigorous phasic activity with indrawing. 5. Vigorous phasic activity with abdominal paradox.
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Esophageal pressure measurement
Description: Esophageal pressure measurement on inspiration and expiration with calculation of delta esophageal pressure, transpulmonary pressure and delta transpulmonary pressure
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Discomfort Visual Analog Scale (VAS)
Description: From 1 to 10 points, where 1 point - maximal discomfort, 10 points - minimal discomfort.
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Noninvasive blood pressure
Description: Noninvasive blood pressure
Study NCT06465264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil/Amlodipine group 1
Description: One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
Study NCT06465264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine group 1
Description: One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
Study NCT06465264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allisartan Isoproxil/Amlodipine group 2
Description: One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
Study NCT06113432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Heart rate
Description: Heart rate calculation using electrocardiogram monitoring
Study NCT04983992 — intervention group
Intervention type: PROCEDURE
Intervention: extracapsular release of lateral retinaculum
Description: A new kind of surgery releases the lateral retinaculum from outside the knee capsular, maintaining the structure of the knee capsular.
Study NCT06199102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol/ Devikap
Description: Infants in the monitored group will receive an initial dose of 1000 IU of vit D. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). At 28±2 days of age, blood samples will be obtained for 25(OH)D concentration measurement, followed by measurements every 4 weeks and/or 35±1 weeks of PCA. In the monitored group, vit D doses will be appropriately modified, based on 25(OH)D levels, using the scheme described in the Polish recommendation. The intake from the diet will be calculated from the second month of life.
Study NCT06199102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol/ Devikap
Description: Infants in the controlled group will receive 250 IU for very low birth weight infants and 500 IU for infants weighing above 1000 g. An additional 160 IU/kg of vit D is included in parenteral nutrition, as well as 150-300 IU/kg in enteral nutrition, depending on the amount and source of enteral feeding (i.e., human milk fortifiers or milk formula). Infants assigned to the standard therapy group will undergo the same blood sample collection procedure as the monitored group, but without any alterations in their dosing regimen.
Study NCT06465264 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil group 2
Description: One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily.
Study NCT04946357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protons
Description: proton irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
Study NCT04946357 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ions
Description: carbon ion irradiation with a total dose of 39 Gy(RBE) in 3 Gy(RBE) fractions
Study NCT05906966 — intervention group
Intervention type: OTHER
Intervention: Phone contact
Description: . All mothers of children of born from cryopreserved oocytes will be contacted by phone and administered a questionnaire, to gather additional information about further psychomotor development of children.
Study NCT05995223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Submaximal exercise protocol
Description: Participants will complete a submaximal walking protocol on a motorized treadmill, which consists of 4 times 6 minutes of walking at a moderate intensity speed and incline while their breathing, cardiac output, and muscle oxygen use is measured, with 10 minutes rest in between each bout.
Study NCT05690620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: Therefore, the laughter yoga program; It was planned as a face-to-face group session, for four (4) weeks, twice a week, for a total of eight (8) sessions and 20-25 minutes.
Study NCT05690620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The students in the control group did not receive any intervention. Nursing students were followed for four weeks. Before the study, data collection tools were applied to the students. Again, after the start of the study and the end of the study, all other data collection tools except the Student Information Form were applied.
Study NCT06275750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal decompression with BTL-6000 spinal decompression system (BTL Industries Ltd.)
Description: The patients were positioned in supine with adjustable lumbar, and thoracic belts attached to the traction cord. After tightening the belts, the M7 position was selected to achieve hip and knee flexion, and posterior pelvic tilt of 25° was added. Before starting the therapy, the weight of the subject was entered in the panel, and a short tolerance test was carried out. Patients were provided with a manual switch to stop treatment any time. Preset lumbar disc herniation protocol was used. Each session lasted fifteen minutes, applied force had 100-gram step increments, and did not exceed 50% of the weight of the patient. At the end of the therapy, the cord was disconnected and belts were removed. Participants were asked to sit for three minutes to identify any adverse reaction.
Study NCT05090514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading and Growth Mindset
Description: Parents and students receive a packet of age-appropriate books and educational materials (flyer/handouts, link to educational video) on how to read together/promote reading with their child using growth mindset strategies and where to find other reading materials. Parents also receive 2 weekly text messages with tips and reminders to read with their child daily for 20 minutes over the course of 8 weeks. The messages contain a link to a secure Redcap survey to log days and time spent reading the prior week.
Study NCT05090514 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list Control
Description: Parents and students receive a packet of age-appropriate books at the same time as the intervention group, but do not receive specialized instruction or reminders to read or any information on growth mindset and reading.
Study NCT04998747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: AMG 701 will be administered as SC or intravenous injection.
Study NCT04998747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: AMG 701 will be administered as SC injection.
Study NCT04907539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXC004
Description: RXC004 will be administered orally, 2 mg QD (Monotherapy); and 1.5 mg QD (Combination therapy)~Dose Formulation: 0.5 mg or 1 mg capsules.
Study NCT04907539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered via IV infusion, 480 mg q4w.
Study NCT04907539 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab will be administered via subcutaneous (SC) injection, 120 mg once every month.~Use: Prophylactic
Study NCT04390945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab combined with concurrent radiotherapy and chemotherapy
Study NCT05711849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow aspiration and a single intracoronary infusion of autologous bone marrow-derived mononuclear cells.
Description: Bone marrow will be harvested from the posterior superior iliac crest under local anaesthetic, and mononuclear cells will be separated using a Ficoll technique in a certified laboratory. Later that same day, the participant will undergo an intracoronary cell infusion of the mononuclear cells. Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the bone marrow aspiration and cell infusion).
Study NCT05711849 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham bone marrow aspiration and sham cell infusion (insertion of vascular access sheath).
Description: These participants will have a sham bone marrow aspiration (a 3mm incision in the skin under local anaesthetic) and a sham intracoronary infusion procedure (the insertion of radial or femoral sheath under local anaesthetic). Participants will be blinded to their treatment arm (they will wear a blindfold and noise cancelling headphones for the sham bone marrow aspiration and sham cell infusion).
Study NCT04984993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED3000 (Male)
Description: Gel formulation
Study NCT04984993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg (Male)
Description: Tablets
Study NCT04984993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MED3000 (Female)
Description: Gel formulation
Study NCT04984993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg (Female)
Description: Tablets
Study NCT05647473 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Participants will be educated on ways to avoid induced hypotensive states, such as avoiding prolonged standing, standing after exercise, being nervous, eating several carbohydrate-rich foods, drinking alcohol, and being in a warm environment (such as a sauna). Participants will be encouraged in a comfortable home environment, such as a sit-down bath. If there are no contraindications, they are advised to increase their salt intake to approximately 10 grams per day and adjust their fluid intake to 2-3 liters per day. They will also be encouraged to perform lower-body strength training and moderate, non-strenuous activities. Seriously ill patients will be proposed to raise the head of their bed during sleep, wear tight clothing, eat small meals, and reduce alcohol intake.Concomitant treatment with cholinesterase inhibitors, memantine, or both was allowed.
Study NCT05647473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: add-on low dose Astragalus
Description: Participants received an additional 10g of astragalus per day.
Study NCT05647473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: add-on high dose Astragalus
Description: Participants received an additional 20g of astragalus per day.
Study NCT05724069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Velusetrag
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Study NCT05724069 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Subjects will be randomly allocated in a blinded fashion to 1 out of the 4 treatment sequences (each sequence include 4 periods, 2 periods with velusetrag and 2 periods with placebo). There will be a wash-out period between each treatment period.
Study NCT04832139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marstacimab PFP
Description: 300 milligrams (mg) subcutaneous injection marstacimab PFP
Study NCT04832139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marstacimab PFS
Description: 300 mg subcutaneous injection of marstacimab PFS
Study NCT04702906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: Standard treatment if indicated.
Study NCT04702906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimetazidine hydrochloride metacardia ® 20 mg tablet
Description: trimetazidine hydrochloride metacardia ® (20 mg three times daily produced by Global NAPI Pharmaceuticals-Egypt)
Study NCT06484010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SNAPPS Model of case presentation
Description: The intervention was the implementation of the SNAPPS model as a method of case presentation in out-patient settings.~All preceptors and residents in the SNAPPS group were sensitized and trained one week before the beginning of case presentations and data collection by a training session that was carried out by the authors at Brayati Primary Health Center training hall for a duration of more than two hours, the session included a preview of the traditional method, introduction to the SNAPPS method, role play and doubts clarification.~The training materials included a presentation explaining the SNAPPS method in details with examples, instructional videos, and handouts highlighting the six steps of the SNAPPS method.~Before the beginning of the presentation by 72 hours, there was a double check by the principal investigator with all participants regarding the method and all doubts were clarified.
Study NCT04907968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XMT-1536 (Upifitamab Rilsodotin)
Description: Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.
Study NCT04907968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Drug: XMT-1536 (Upifitamab Rilsodotin) XMT-1536 (Upifitamab Rilsodotin) will be administered on Day 1 of each 28-day cycle until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study~Other Names:~* XMT-1536~* UpRi Drug: Carboplatin Carboplatin will be administered on Day 1 on each of the first six 28 day cycles.
Study NCT05915624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telephone counseiling
Description: One day before the operation, information was given about the operation process via tele-nursing and counseling was provided.
Study NCT06228040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preanaesthetic teleconsultation
Description: Pre-anaesthetic consultation by telephone for eligible patients according to the criteria set
Study NCT06228040 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: preanaesthetic classical physical consultation
Description: Pre-anaesthetic classical consultation before teleconsultation implementation
Study NCT04905212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 160mg
Description: Subcutaneous injection Telitacicept 160mg. The injection site can be at the thigh, abdomen, or upper arm.
Study NCT04905212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telitacicept 240mg
Description: Subcutaneous injection Telitacicept 240mg. The injection site can be at the thigh, abdomen, or upper arm.
Study NCT04905212 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection placebo. The injection site can be at the thigh, abdomen, or upper arm.
Study NCT05846906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: oral sildenafil (Respatio® 20mg )
Study NCT05846906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate 50mg
Description: used for ovionulation induct
Study NCT05846906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Clomiphene Citrate 50mg
Description: used for ovionulation induct
Study NCT05259761 — intervention group
Intervention type: OTHER
Intervention: Unmanned ariel vehicle
Description: Use of an Unmanned ariel vehicle for medical delivery (drugs and samples)
Study NCT05472077 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lollipop Swab
Description: The lollipop swab is a typical swab that would be used to obtain routine pharyngeal samples. Participants are instructed to suck on the swab for 20 second, as they would suck on a lollipop.
Study NCT05913180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid 1000 MG
Description: 1000mg Ascorbic acid orally daily started on the day of elective gynecological surgery for 10 days
Study NCT05913180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet daily starting day of elective gynecological surgery for 10 days
Study NCT05675761 — intervention group
Intervention type: DRUG
Intervention: Azorubine
Description: Azovudine tablets, 1mg /tablet, 5 tablets, QD+basic treatment (14 days at most)